全球胚胎著床前基因檢測市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計胚胎著床前基因檢測 (PGD) 市場將從 2025 年的 1021510000 美元成長到 2034 年的 2587760000 美元，2026 年至 2034 年的複合年成長率為 10.88%。

隨著輔助生殖技術的進步和廣泛應用，全球胚胎胚胎著床前遺傳學檢測（PGT）市場正在快速成長。 PGT用於體外受精（IVF）過程中，在胚胎胚胎著床前胚胎著床前篩檢是否有遺傳異常。這一過程有助於提高妊娠成功率並降低遺傳疾病的風險。

該市場的主要促進因素是全球遺傳疾病和不孕症問題日益增加。隨著人們對基因篩檢的認知不斷提高，越來越多的患者選擇先進的輔助生殖技術。此外，基因測序和基因分析技術的進步也提高了胚胎植入前遺傳學篩檢（PGT）的準確性和可靠性。

未來，隨著生殖醫學的進步，胚胎著床前遺傳學檢測（PGT）市場預計將顯著成長。對個人化生殖醫學日益成長的需求以及體外受精成功率的提高將推動市場成長。遺傳學和生殖生物學領域的持續研究也可能為先進的胚胎篩檢技術創造新的機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球胚胎著床前基因檢測市場：依類型分類

• 市場分析、洞察與預測
• 染色體異常
• 非整倍體
• X連鎖疾病
• 單基因疾病
• HLA型檢測
• 性別選擇
• 其他

第5章 全球胚胎著床前基因檢測市場：依最終用戶分類

• 市場分析、洞察與預測
• 診斷檢查室
• 醫院
• 診所
• 其他

第6章 全球胚胎著床前基因檢測市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • Agilent Technologies Inc
  • PerkinElmer Inc
  • CooperSurgical Inc
  • Abbott Laboratories
  • Natera Inc
  • Takara Bio
  • Oxford Gene Technology
  • Yikon Genomics
  • Progenesis
  • Beijing Genomics Institute（BGI）
  • Invitae Corporation
  • Invicta Genetics
  • Genea Limited

The Preimplantation Genetic Testing Market size is expected to reach USD 2587.76 Million in 2034 from USD 1021.51 Million (2025) growing at a CAGR of 10.88% during 2026-2034.

The global preimplantation genetic testing market is growing rapidly as assisted reproductive technologies become more advanced and widely adopted. Preimplantation genetic testing (PGT) is used during in vitro fertilization (IVF) to screen embryos for genetic abnormalities before implantation. This process helps improve the chances of a successful pregnancy and reduces the risk of genetic disorders.

A major driver of the market is the increasing prevalence of genetic diseases and infertility issues among couples worldwide. As awareness of genetic screening increases, more patients are opting for advanced reproductive technologies. Additionally, improvements in genomic sequencing and genetic analysis technologies have made PGT more accurate and reliable.

Looking ahead, the preimplantation genetic testing market is expected to expand significantly as reproductive medicine continues to advance. The growing demand for personalized reproductive healthcare and improved IVF success rates will support market growth. Ongoing research in genetics and reproductive biology will likely create new opportunities for advanced embryo screening technologies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Chromosomal Abnormalities
• Aneuploidy
• X-Linked Diseases
• Single Gene Disorders
• Hla Typing
• Gender Selection
• Others

By End User

• Diagnostic Laboratories
• Hospitals
• Clinics
• Others

COMPANIES PROFILED

• Illumina Inc, Thermo Fisher Scientific Inc, Agilent Technologies Inc, PerkinElmer Inc, CooperSurgical Inc, Abbott Laboratories, Natera Inc, Takara Bio, Oxford Gene Technology, Yikon Genomics, Progenesis, Beijing Genomics Institute BGI, Invitae Corporation, Invicta Genetics, Genea Limited
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Chromosomal Abnormalities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Aneuploidy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. X-Linked Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Single Gene Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Hla Typing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Gender Selection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY END USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End User
• 5.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By End User
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By End User
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By End User
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By End User
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By End User
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PREIMPLANTATION GENETIC TESTING INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Illumina Inc
  • 8.2.2 Thermo Fisher Scientific Inc
  • 8.2.3 Agilent Technologies Inc
  • 8.2.4 PerkinElmer Inc
  • 8.2.5 CooperSurgical Inc
  • 8.2.6 Abbott Laboratories
  • 8.2.7 Natera Inc
  • 8.2.8 Takara Bio
  • 8.2.9 Oxford Gene Technology
  • 8.2.10 Yikon Genomics
  • 8.2.11 Progenesis
  • 8.2.12 Beijing Genomics Institute (BGI)
  • 8.2.13 Invitae Corporation
  • 8.2.14 Invicta Genetics
  • 8.2.15 Genea Limited